Transthera Sciences (Nanjing), Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Nanjing Transthera Biosciences Co., Ltd. (to 2022)
0
Ending by 2030
Aug 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Halo-allylamine SSAO/VAP-1 inhibitor and use thereof (US 11,649,233) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Method for treating a cancer mediated by abnormality of multi-kinases (US 11,718,620) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,744,139 | Inhibitors of fibroblast growth factor receptor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,208,042 | Multi-kinase inhibitor compound, and crystal form and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,889,586 | Multi-kinase inhibitor compound, and crystal form and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,434,248 | PDE9 Inhibitor and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,718,620 | Method for treating a cancer mediated by abnormality of multi-kinases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,889,591 | PDE9 Inhibitor and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,649,233 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,420,975 | Substituted imidazo[1,5-a]pyrazines as Bruton's tyrosine kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,780,797 | Novel Quinoline Derivative Inhibitor In force · High confidence | In force | High confidence | |
| US 12,291,534 | Aminonorbornane Derivative and Manufacture Method Therefor and Use Thereof In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 4 no status recorded